Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 65,700 shares, a decline of 82.5% from the April 30th total of 376,100 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 35,300 shares, the days-to-cover ratio is currently 1.9 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price (down from $11.50) on shares of Innate Pharma in a report on Thursday, April 24th.
Check Out Our Latest Analysis on Innate Pharma
Innate Pharma Stock Performance
NASDAQ:IPHA traded down $0.04 during trading hours on Friday, reaching $2.16. 8,120 shares of the company were exchanged, compared to its average volume of 186,457. Innate Pharma has a twelve month low of $1.29 and a twelve month high of $3.51. The stock's 50-day moving average is $2.04 and its 200-day moving average is $1.94.
Innate Pharma Company Profile
(
Get Free Report)
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Featured Articles
Before you consider Innate Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.
While Innate Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.